ClinicalTrials.gg
CompletedNCT02473952Updated Mar 5, 2019Results posted

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

A Phase 2 interventional study of IGIV-C and Placebo in Myasthenia Gravis, Generalized, sponsored by Grifols Therapeutics LLC. Completed at 40 sites in 10 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-03-05.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Enrollment
51st of 108
62 · median 56
Started
2015
with 3 others
Phase 2
26 of 144
5 open now
Registered
23rd of 144
by date

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 51st largest by enrollment of the 108 interventional ones that give a count, is one of 4 that started in 2015, is one of 26 in phase 2, and was the 23rd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.

Read the detailed description

The primary objective is to evaluate the efficacy of IGIV-C in subjects with generalized myasthenia gravis (MG) on standard of care treatment at study entry in terms of improvement in MG symptoms as measured by the mean change in Quantitative Myasthenia Gravis (QMG) score from Baseline (Week 0) to Week 24 as compared to placebo.

The safety objective of this study is to evaluate the safety and tolerability of IGIV-C loading dose of 2 g/kg followed by 7 maintenance dosages of 1 g/kg every 3 weeks through Week 21 in subjects with MG.

03

Conditions studied

  • Myasthenia Gravis, Generalized

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Anti-acetylcholine receptor (AChR) antibody positive
  • Confirmed diagnosis of generalized myasthenia gravis (MG).
  • Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa inclusive at Screening.
  • QMG >= 10 at Screening. Note: Subjects who only have a history of ocular MG may not enroll.
  • Receiving standard of care MG treatment at a stable dose consisting of any one of the following for the time intervals delineated below (time intervals apply to medications and maintenance of stable dose level):

    1. Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks prior to Screening and no
    2. Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks prior to Screening AND/OR only one of the following:

      1. Prednisone (up to 60 mg/day or equivalent) for at least 2 months prior to Screening, OR
      2. Azathioprine for at least 6 months prior to Screening, OR
      3. Mycophenolate mofetil for at least 6 months prior to Screening, OR
      4. Methotrexate for at least 6 months prior to Screening, OR
      5. Cyclosporine or tacrolimus for at least 3 months prior to Screening
    3. Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks prior to Screening AND/OR prednisone (up to 60 mg/day or equivalent) for at least one month prior to Screening and only one of the following:

      1. Azathioprine for at least 6 months prior to Screening, OR
      2. Mycophenolate mofetil for at least 6 months prior to Screening, OR
      3. Methotrexate for at least 6 months prior to Screening, OR
      4. Cyclosporine or tacrolimus for at least 3 months prior to Screening

Exclusion criteria

Exclusion Criteria:

  • Have received cyclophosphamide or any other agent apart from the ones allowed per inclusion criteria within the past 6 months
  • Any change in MG treatment regimen between Screening (Week -3, Visit 0) and Baseline (Week 0, Visit 1)
  • Greater than two point change in QMG score, increased or decreased, between Screening (Week -3, Visit 0) and Baseline (Week 0, Visit 1)
  • Any episode of myasthenic crisis in the one month prior to Screening
  • Evidence of within the past 5 years (non-melanoma skin cancer, carcinoma in situ of cervix is allowed) or thymoma potentially requiring surgical intervention during the course of the trial (intent to perform thymectomy)
  • Thymectomy within the preceding 6 months
  • Rituximab, belimumab, eculizumab or any monoclonal antibody used for immunomodulation within the past 12 months
  • Have received immune globulin (Ig) treatment given by intravenous (IV), subcutaneous, or intramuscular route within the last 3 months
  • Current known hyperviscosity or hypercoagulable state
  • Currently receiving anti-coagulation therapy (vitamin K antagonists, nonvitamin K antagonist oral anticoagulants [e.g., dabigatran etexilate, rivaroxaban, edoxaban, and apixaban], parenteral anticoagulants [e.g., fondaparinux]). Note that oral anti- agents are allowed (e.g., aspirin, clopidogrel, ticlodipine)
  • Documented diagnosis of thrombotic complications to polyclonal intravenous immunoglobulin (IVIg) therapy in the past
  • History of recent (within the last year) myocardial infarction or stroke
  • Uncontrolled congestive heart failure; embolism; or historically documented (within the last year) (ECG) changes indicative of myocardial ischemia or atrial fibrillation
  • History of chronic alcoholism or illicit drug abuse (addiction) in the 12 months preceding the Screening/Week -3 (Visit 0)
  • Plasma exchange (PLEX) performed within the last 3 months
  • Renal impairment (i.e., serum creatinine exceeds more than 1.5 times the [ULN] for the expected normal range for the testing laboratory).
  • levels less than 9 g per dL
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    IGIV-C

    IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified. An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8).

    Drug: IGIV-C

  • Placebo comparator
    Placebo

    Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).

    Drug: Placebo

Interventions

  • DrugIGIV-C

    IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Improvement in Myasthenia Gravis (MG) Symptoms as Measured by the Mean Change in Quantitative Myasthenia Gravis (QMG) Total Score.

    To measure improvement in MG symptoms by the mean change in QMG total score from Baseline (Week 0) to Week 24 as compared to placebo. Evaluators score 13 individual items (range from 0=best to 3=worst) and the individual scores are added together for the total score (range 0-39). An average 3-point improvement in QMG score indicates clinically meaningful improvement.

    Time frame: Baseline (Week 0) to Week 24

07

Results

Posted Mar 5, 2019

Participant flow

Participant flow — Overall Study
MilestoneIGIV-CPlacebo
Started3032
Completed2824
Not completed28
Withdrew: Adverse event22
Withdrew: Withdrawal by subject06

Outcome measures

PrimaryImprovement in Myasthenia Gravis (MG) Symptoms as Measured by the Mean Change in Quantitative Myasthenia Gravis (QMG) Total Score.

To measure improvement in MG symptoms by the mean change in QMG total score from Baseline (Week 0) to Week 24 as compared to placebo. Evaluators score 13 individual items (range from 0=best to 3=worst) and the individual scores are added together for the total score (range 0-39). An average 3-point improvement in QMG score indicates clinically meaningful improvement.

Time frame:
Baseline (Week 0) to Week 24
Reported as:
Mean · units on a scale
Improvement in Myasthenia Gravis (MG) Symptoms as Measured by the Mean Change in Quantitative Myasthenia Gravis (QMG) Total Score.
units on a scaleIGIV-CPlacebo
Improvement in Myasthenia Gravis (MG) Symptoms as Measured by the Mean Change in Quantitative Myasthenia Gravis (QMG) Total Score.-4.6 ± 5.11-2.7 ± 6.23

Adverse events

Collected over Adverse event data were collected from screening through Week 24.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGIV-C1/30 (3.3%)5/30 (16.7%)22/30 (73.3%)
Placebo0/32 (0%)4/32 (12.5%)21/32 (65.6%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventIGIV-CPlacebo
Myasthenia gravisNervous system disorders3/301/32
Atrial fibrillationCardiac disorders1/300/32
Cardiopulmonary failureCardiac disorders1/300/32
Haemorrhoids thrombosedGastrointestinal disorders1/300/32
PneumoniaInfections and infestations1/300/32
Septic shockInfections and infestations1/300/32
Panic attackPsychiatric disorders1/300/32
Lower limb fractureInjury, poisoning and procedural complications0/301/32
Wrist fractureInjury, poisoning and procedural complications0/301/32
Ischaemic strokeNervous system disorders0/301/32
Most frequent other events
Showing 10 of 18
Most frequent other events
EventIGIV-CPlacebo
HeadacheNervous system disorders9/304/32
NasopharyngitisInfections and infestations3/304/32
DiarrhoeaGastrointestinal disorders3/302/32
NauseaGastrointestinal disorders3/301/32
CoughRespiratory, thoracic and mediastinal disorders3/300/32
HypertensionVascular disorders3/302/32
Upper respiratory tract infectionInfections and infestations0/303/32
ChillsGeneral disorders2/300/32
FatigueGeneral disorders2/300/32
ArthralgiaMusculoskeletal and connective tissue disorders2/300/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)IGIV-CPlaceboTotal
Mean54.6 ± 17.0648.0 ± 13.6651.2 ± 15.63
Age, Customized
Age, Customized(Participants)IGIV-CPlaceboTotal
<65 years202949
>=6510313
Sex: Female, Male
Sex: Female, Male(Participants)IGIV-CPlaceboTotal
Female141933
Male161329
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IGIV-CPlaceboTotal
Hispanic or Latino235
Not Hispanic or Latino282957
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IGIV-CPlaceboTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander011
Black or African American101
White293059
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)IGIV-CPlaceboTotal
North America111223
Europe192039
08

Study locations

40 sites
  • Phoenix Neurological Associates, Ltd.
    Phoenix, Arizona 85018, United States
  • University of California-Irvine
    Orange, California 92868, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • University of Florida Health Science Center
    Jacksonville, Florida 32209, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center Research Institute, Inc.
    Kansas City, Kansas 66160, United States
  • Rutgers New Jersey Medical School
    Newark, New Jersey 07103, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Ohio State University Wexner Medical Center
    Columbus, Ohio 43220, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Houston Methodist Neurological Institute
    Houston, Texas 77030, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05405, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • UZ Leuven
    Leuven, 3000, Belgium
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
  • University Health Network (UHN) - Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Fakultni nemocnice Brno, Dept of Neurologicka klinika
    Brno, 625 00, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava - Poruba, 708 52, Czechia
  • East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • CHU Nice - Hôpital de l'Archet 1, Ctre de Réf Maladies Neuromusculaires et SLA
    Nice cedex 3, Alpes Maritimes 6202, France
  • CHU Strasbourg - Nouvel Hôpital Civil, Clinique Neurologique
    Strasbourg cedex, Bas Rhin 67091, France
  • CHU de Toulouse - Hôpital Purpan, Service de Neurologie Générale
    Toulouse cedex 9, Haute Garonne 31059, France
  • Hopital Neurologique Pierre Wertheimer, Neuro-musculaire - Electromyographie
    Bron cedex, Rhone 69677, France
  • Universitaetsklinikum Regensburg, Parent
    Regensburg, Bayern 93053, Germany
  • Universitaetsmedizin Göttingen, Parent
    Göttingen, Niedersachsen 37075, Germany
  • Universitaetsklinikum Koeln, Neurologie und Psychiatrie
    Koeln, Nordrhein Westfalen 50937, Germany
  • Krankenhaus Martha-Maria Halle-Doelau, Klinik fuer Neurologie
    Halle, Sachsen Anhalt 6120, Germany
  • Universitaetsklinikum Carl Gustav Carus TU Dresden
    Dresden, Sachsen 1307, Germany
  • Universitaetsklinikum Jena, Klinik fuer Neurologie
    Jena, Thueringen 7747, Germany
  • Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik fuer Neurologie
    Hamburg, 20246, Germany
  • Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Neurologiai Osztaly
    Budapest, 1204, Hungary
  • Pest Megyei Flor Ferenc Korhaz, Neurologia es Stroke Osztaly
    Kistarcsa, 2143, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, 6725, Hungary
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
    Kaunas, 50009, Lithuania
  • Uniwersyteckie Centrum Kliniczne, Dept of Neurology
    Gdansk, 80-952, Poland
  • Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii Klinicznej
    Krakow, 31-505, Poland
  • III Szpital Miejski w Lodzi im. Dr K. Jonschera
    Lodz, 93-113, Poland
  • Samodzielny Publiczny Centralny Szpital Kliniczny, Dept of Neurology
    Warszawa, 02-097, Poland
09

References and documents

Publications

  • Dalakas MC, Meisel A. Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis. Expert Rev Neurother. 2022 Apr;22(4):313-318. doi: 10.1080/14737175.2022.2057223. Epub 2022 Apr 5. PubMed 35350948 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Jan 2018, 29 months.

Results were first posted in Mar 2019, 1 year 2 months after primary completion.

Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2015
First posted
Jun 17, 2015
StartActual
Aug 2015
Primary completionActual
Jan 2018
CompletionActual
Jan 2018
Results first posted
Mar 5, 2019
Last update
Mar 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02473952
Responsible party
Sponsor
First posted
Jun 17, 2015
Start date
Aug 2015
Primary completion
Jan 2018
Completion
Jan 2018
Results posted
Mar 5, 2019
Last update
Mar 5, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion